Masimo Management

Management criteria checks 2/4

Masimo's CEO is Michelle Brennan, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.002% of the company’s shares, worth R$1.13M. The average tenure of the management team and the board of directors is 6.8 years and 0.2 years respectively.

Key information

Michelle Brennan

Chief executive officer

US$243.8k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.002%
Management average tenure	6.8yrs
Board average tenure	less than a year

Recent management updates

Recent updates

CEO

Michelle Brennan (58 yo)

less than a year

Tenure

US$243,770

Compensation

Ms. Michelle M. Brennan is Interim CEO & Director of Masimo Corporation from October 24, 2024. Ms. Michelle M. Brennan served as an Independent Director at Coupa Software Incorporated since October 2020. u...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michelle Brennan	Interim CEO & Director	less than a year	US$243.77k	0.0023% R$ 1.1m
Micah Young	Executive VP & CFO	7.1yrs	US$3.36m	0.020% R$ 9.7m
Bilal Muhsin	Chief Operating Officer	5.5yrs	US$3.39m	0.032% R$ 16.0m
Thomas McClenahan	Executive VP	11.6yrs	US$3.26m	0.045% R$ 22.3m
Tao Levy	Executive Vice President of Business Development	6.8yrs	US$2.13m	0.050% R$ 24.8m
Paul Hataishi	Senior VP & Chief Accounting Officer	1.8yrs	no data	no data
Yongsam Lee	Executive VP & Chief Information Officer	22.6yrs	US$1.49m	no data
Steven Barker	Chairman of Scientific Advisory Board & Chief Science Officer	9.7yrs	US$139.56k	no data
Eli Kammerman	Vice President of Business Development & Investor Relations	15.4yrs	no data	no data
Anand Sampath	Executive Vice President of Operations & Clinical Research	5.5yrs	US$1.97m	no data
Blair Tripodi	Chief Operating Officer of Consumer Division	2.2yrs	no data	no data
Tetsuro Maniwa	President of Masimo Japan	no data	no data	no data

6.8yrs

Average Tenure

51yo

Average Age

Experienced Management: M2AS34's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michelle Brennan	Interim CEO & Director	1.4yrs	US$243.77k	0.0023% R$ 1.1m
Steven Barker	Chairman of Scientific Advisory Board & Chief Science Officer	no data	US$139.56k	no data
William Jellison	Director	less than a year	no data	no data
Christopher Chavez	Director	less than a year	no data	no data
Craig Reynolds	Lead Independent Director	10.6yrs	US$305.84k	0.035% R$ 17.2m
Wendy Lane	Director	less than a year	no data	no data
Timothy Scannell	Director	less than a year	no data	no data
Robert Chapek	Independent Director	less than a year	no data	no data
Darlene J. Solomon	Director	less than a year	no data	no data
Quentin Koffey	Independent Director	1.4yrs	US$242.48k	0.0023% R$ 1.1m

0.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: M2AS34's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.

Masimo Management

Management criteria checks 2/4

Key information

Recent management updates

Masimo Corporation Announces Board of Directors Appointments

Masimo Corporation Announces CEO Changes

Masimo Corporation Removes Joe Kiani as the Chief Executive Officer

Masimo Corporation, Annual General Meeting, Jul 25, 2024

Masimo Corporation, Annual General Meeting, Jul 25, 2024

Masimo Corporation Announces Changes to its Board

Recent updates

Masimo Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Masimo Corporation to Report Q3, 2024 Results on Nov 05, 2024

Masimo Corporation Announces Board of Directors Appointments

Masimo Corporation Announces CEO Changes

Politan Capital Comments on Results of Masimo’s Annual Meeting

Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote

Politan Capital Issues Statement from Legal Advisors Schulte Roth & Zabel and Munger, Tolles & Olson Regarding Masimo Corporation Proxy Contest

Politan Provides Update on Why Masimo Shareholders Should Support Urgently Needed Board Change at Company’s 2024 AGM

Masimo W1 Medical Watch Receives Fda 510(K) Clearance for Connectivity to the Masimo Safetynet Telemonitoring System

Masimo Corporation Provides Earnings Guidance for the Third-Quarter and Full-Year 2024

Masimo Announces New Study Finds That Remote Patient Monitoring with Masimo Safetynet® Significantly Reduced Rates of Hospital Readmission and Ed Visits for Patients Recuperating At Home After Joint Replacement Surgery

Masimo Corporation to Report Q2, 2024 Results on Aug 06, 2024

Politan Capital Management Files a Lawsuit in the Delaware Court of Chancery Against Masimo Corporation

Politan Capital Management Sends a Letter to the Board of Masimo Corporation

Masimo Corporation Announces Class Action Lawsuit Filed on Behalf of Investors

Politan Capital Sends a Letter to the Board of Masimo Corporation

Politan Capital Issues Investor Presentation with Shareholders of Masimo Corporation

Masimo Corporation Removes Joe Kiani as the Chief Executive Officer

Politan Capital Sends a Letter to Shareholders of Masimo Corporation

Masimo Corporation, Annual General Meeting, Jul 25, 2024

Masimo Corporation, Annual General Meeting, Jul 25, 2024

Masimo Corporation Provides Update on Voluntary Recall of Select Rad-G Products

Masimo Corporation Announces Changes to its Board

Masimo and Denon Introduces White PerL and PerL Pro™ Earbuds

Politan Capital Management Threatens Masimo Corporation with Legal Action

Masimo Corporation Provides Earnings Guidance for the Second Quarter 2024 and Updates Earnings Guidance for the Full-Year 2024

Masimo Receives FDA Clearance for Stork Over-the-Counter (OTC) Baby Monitoring System

Masimo Corporation to Report Q1, 2024 Results on May 07, 2024

Masimo Corporation Reaffirms Financial Guidance for the First Quarter and Fiscal Year 2024

Masimo Corporation(NasdaqGS:MASI) dropped from FTSE All-World Index (USD)

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth-Quarter and Full-Year 2024

Masimo Corporation Announces Board Changes

Masimo Announces the First FDA-Cleared “Over-The-Counter” Fingertip Pulse Oximeter

Masimo Corporation to Report Q4, 2023 Results on Feb 27, 2024

Masimo Announces Reinstatement of Import Ban on Infringing Apple Watches

Masimo Corporation Appoints Bob Chapek to the Board of Directors

Masimo Corporation Provides Consolidated Earnings Guidance for the Fourth Quarter and Full Year Ended December 30, 2023 and Full Year 2024

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

Masimo W1™ Medical Watch Receives FDA 510(K) Clearance for Over-The-Counter and Prescription Use

Masimo Corporation Provides Earnings Guidance for the Fourth-Quarter and Full-Year 2023

Masimo Corporation to Report Q3, 2023 Results on Nov 07, 2023

Howard G. Smith Announces Securities Fraud Lawsuit Against Masimo Corporation

Masimo ORi™ Granted De Novo as the First and Only FDA-Cleared Noninvasive and Continuous Parameter to Provide Insight into Hyperoxia Under Supplemental Oxygen

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Masimo Corporation

Masimo Corporation Provides Earnings Guidance for the Third-Quarter and Full-Year 2023

Masimo Corporation to Report Q2, 2023 Results on Aug 08, 2023

Masimo Corporation Approves Board Elections

Masimo Corporation(NasdaqGS:MASI) dropped from Russell Small Cap Comp Value Index

Masimo Expands into the Personalized Hearables Market with Denon Perl™? True Wireless Earbuds, Featuring Masimo Aat™?

Politan Capital Management Sends a Letter to Shareholders of Masimo Corporation

Masimo Corporation Appoints Michelle Brennan as Sixth Director

Politan Capital Management LP Posts Presentation to the Website

Politan Capital Releases Investor Presentation to Shareholders of Masimo Corporation

Masimo Corporation Provides Earnings Guidance for the Full Year of 2023

Politan Capital Launches a Website in Connection with the Solicitation of Stockholders

Politan Capital Management Nominates Candidates for Masimo Board

Masimo Corporation to Report Q4, 2022 Results on Feb 28, 2023

Masimo Corporation Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)

Masimo Announces New Study Evaluates the Performance of Masimo Sphb Noninvasive Spot-Check Hemoglobin in the Emergency Department

Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality

Masimo Announces New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section

Masimo Announces Launch of the Expansion of the HEOS Platform to Provide Robust and Always-On Connection to the Masimo Health Secure Cloud

Masimo Corporation Announces Full Market Release of Hydration Index for the Masimo W1 Advanced Health Tracking Watch

Peer-Reviewed Study Finds That Masimo Set® Pulse Oximetry Has No Clinically Significant Difference in Accuracy or Bias Between Black and White People

Masimo Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Masimo Corporation to Report Q3, 2022 Results on Nov 08, 2022

Politan Capital Files Verified Complaint in the Delaware Court of Chancery Against Masimo Corporation

Masimo Corporation Provides Information to Shareholders

Masimo Corporation Appoints Blair Tripodi as Chief Operating Officer, Consumer Division